Institutional Clinical and Translational Science Award

机构临床和转化科学奖

基本信息

批准号：
10348879
负责人：
GARRET A FITZGERALD
金额：
$ 1016.45万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-07-01 至 2026-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10348879
关键词：
Academia Address Adherence Adult Antihypertensive Agents Area Biological Models Cell model Childhood Circadian Dysregulation Clinical Clinical Research Clinical Sciences Clinical and Translational Science Awards Communities Complex Development Disadvantaged Discipline Disease Dose Drug Exposure Educational process of instructing Faculty First Independent Research Support and Transition Awards Fostering Fruit Functional disorder Funding Genomic medicine Goals Growth Health system Home Human Incentives Industry Institutes Institution Intensive Care Intervention Trial Leadership Life Lipids London Measures Messenger RNA Mission Modeling Pediatric Hospitals Pennsylvania Pharmaceutical Preparations Pharmacologic Substance Phenotype Philadelphia Physiological Physiology Pilot Projects Price Private Sector Randomized Research Research Personnel Resources Rural Community Schools Science Series Sickle Cell Anemia Testing The Wistar Institute Therapeutic Time Translating Translational Research United States National Institutes of Health Universities Urban Community Validation Vision cardiovascular risk factor clinical implementation clinical investigation college drug action implementation barriers implementation science improved improved outcome medical schools novel novel therapeutics phenomics pre-clinical precision medicine programs recruit response success translational medicine uptake

项目摘要

Contact PD/PI: FITZGERALD, GARRET A OVERALL ABSTRACT/SUMMARY The Institute for Translational Medicine and Therapeutics is the academic home for the CTSA in Penn. For the past decade and a half the objectives of ITMAT have been and remain (i) to increase the number of investigators capable of pursuing their research between proof of concept in cells and model systems and (ii) elucidation of the mechanisms of human physiology, disease or drug action through intense phenotyping in small numbers of people. The two priorities of our CTSA are to foster the field of translational therapeutics and to bridge the pediatric to adult divide across the entire spectrum of clinical and translational science. This section describes how these priorities have influenced the growth of this CTSA Hub and outlines our plans for the coming funding period. Project Summary/Abstract Page 136 Contact PD/PI: FITZGERALD, GARRET A OVERALL NARRATIVE The Institute for Translational Medicine and Therapeutics is the academic home for the CTSA in Penn. For the past decade the specific aims of ITMAT have been and remain (i) to increase the number of investigators capable of pursuing their research between proof of concept in cells and model systems and (ii) elucidation of the mechanisms of human physiology, disease or drug action through intense phenotyping in small numbers of people.

联系PD/PI：Fitzgerald，Garret A 全面的摘要/摘要转化医学与治疗学研究所是CTSA的学术意义宾夕法尼亚在过去的十年半中增加了能够在证明证明之间进行研究的调查人员的数量细胞和模型系统中的概念以及（ii）阐明人类生理机制的概念，疾病或药物作用通过少数人的强烈表型来作用。两个我们CTSA的优先事项是促进转化治疗领域并桥接在整个临床和转化科学范围内，小儿到成人分裂。这部分描述了这些优先级如何影响该CTSA枢纽和轮廓的增长我们在即将到来的资金期间的计划。项目摘要/摘要页面136 联系PD/PI：Fitzgerald，Garret A 全面的叙述转化医学与治疗学研究所是CTSA的学术意义宾夕法尼亚在过去的十年中能够在细胞中概念证明之间进行研究的研究人员数量以及模型系统以及（ii）阐明人类生理学，疾病或通过少数人的强烈表型来采取毒品作用。